Traditional benchmarking approaches are often outdated and overly optimistic, leading to poor investment decisions. Learn how we're setting the bar higher with Dynamic Benchmarks. Better benchmarking = better pharma decision-making. Read more ??
Intelligencia AI
软件开发
New York，New York 12,131 位关注者
Applying machine learning in drug development
关于我们
Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making. We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies. Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.
- 网站
-
https://www.intelligencia.ai/
Intelligencia AI的外部链接
- 所属行业
- 软件开发
- 规模
- 51-200 人
- 总部
- New York，New York
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Artificial Intelligence、Data Science、Machine Learning、Data Visualization、Experience Design、Healthcare、Pharmaceuticals、Biotechnology、Drug Development和Clinical Trials
地点
Intelligencia AI员工
-
Aristotelis Tsirigos
Professor at NYU School of Medicine.
-
Dimitrios Skaltsas
We are hiring! Co-Founder & CEO, Intelligencia AI: De-risking drug development| Inc. 5000| Executive in Residence, AI at INSEAD
-
Panos Karelis
Bringing best-in-class insights to biopharma | Director of Insights Excellence at Intelligencia.ai
-
Alexandra Ferraro
Strategic and Tactical Marketing Leader ?? Data-Driven Strategist ?? Market Expansion and Vertical Growth Leader ??Experienced Full-Stack Marketing…
动态
-
This week, take 20 minutes to get some fresh air and expand your knowledge by listening to Panos Karelis of Intelligencia AI and Matthew DeMello of Emerj Artificial Intelligence Research as they chat about challenges and immense opportunities in de-risking and accelerating #drugdevelopment.
“Accelerate and Mitigate Risk in Clinical Development - with Panos Karelis of Intelligencia AI” https://lnkd.in/dwJUBHie AI is reshaping drug development by addressing long-standing challenges in cost, efficiency, and decision-making. The process of bringing a drug to market remains expensive and time-consuming, often exceeding a decade and billions in investment. Despite scientific advancements, many decisions still rely on fragmented data and subjective judgment. AI has the potential to change this by providing transparent, data-driven insights that improve success rates and resource allocation. Panos Karelis, Director of Customer Experience and Insights at Intelligencia AI joins this week’s ‘#AIinBusiness’ podcast to discuss the key barriers to AI adoption in pharmaceutical development. He highlights the importance of explainability in AI models, the need for high-quality, harmonized data, and the organizational shift required to integrate AI-assisted decision-making. He also explores AI’s role in optimizing clinical trial design, enhancing portfolio management, and improving business development strategies for pharmaceutical companies. #AI #MachineLearning #DrugDevelopment #PharmaAI #ClinicalTrials #HealthcareInnovation #PharmaceuticalIndustry #Biotech #DataScience #AIinHealthcare #DecisionMaking #DigitalTransformation #LifeSciences #AIinBusiness #Innovation
-
-
Catch Angeliki Lykoudi at #BioEuropeSpring and hear how we're supporting #pharmaceutical companies to advance drug development by reducing risk and accelerating timelines. Learn more about what makes us tick??https://lnkd.in/eVesQ6BD
Leveraging AI to improve decision making in pharma | MSc in Pharmacology & Toxicology
I just registered for BIO-Europe Spring on March 17–19, 2025. Join me at the premier springtime partnering event >> https://lnkd.in/dhQi4ZqY #BIOEuropeSpring Informa Connect
-
-
Next month, Dorita Metallinou, Maria Georganaki, PhD, Angeliki Lykoudi and Marianna Esposito will head to Basel to learn from #pharmaceutical leaders in project and portfolio management, and they'll share how we're working with the industry to de-risk drug development and accelerate clinical development.
After an inspiring first day at Pharma PPM Toolbox, it’s time to relax, connect, and enjoy the evening! Grab a drink, join the conversations, and have fun meeting fellow project and portfolio management professionals. Don’t forget your business cards – you never know who you’ll connect with! Sponsored by Intelligencia AI, this evening is the perfect opportunity to expand your network in a casual and friendly setting. #PharmaPPM2025 #InnovationInPharma #LeadershipInAction
-
-
In our latest research with ZS, we examined over 20,000 industry-sponsored interventional #oncology clinical programs and identified the various impacts of seven different strategic #clinicaldevelopment decisions. Setting aside competitive dynamics, each month a program can accelerate to market adds an estimated $5-6M of net present value per billion dollars of peak year sales. Explore what else we uncovered (link below).
-
-
Did you know that February marks #BileDuctCancerAwareness? Gallbladder cancer and bile duct cancer are relatively rare forms of cancer, with an estimated 12,350 cases of both types combined diagnosed in 2024, according to the?National Cancer Institute?(NCI). Here are some organizations with patient and caregiver resources on this rare disease: ?? American Association for Cancer Research ??National Cancer Institute (NCI) ?? The George Washington University Cancer Center ?? National Foundation for Cancer Research (NFCR)
-
The sun is shining (and our team is smiling) in New Jersey at the?Marcus Evans Group?conference, and the day isn't over yet!?Cheers to day 2 in fostering connections with #portfoliostrategy professionals in #pharmaceutical industry.
-
-
This week, we're in the Garden State sponsoring marcus evans Group's Project Portfolio and Resource Management Excellence for Pharma and Biotech. Edoardo Madussi?will take the stage tomorrow to talk about applications of data and?#AI?to optimize portfolio strategy in?#pharma. If you're not going to be there but you're interested in a copy of our presentation, let us know: https://lnkd.in/dUMiUpez
-
-
In an analysis comparing our Dynamic Benchmarks to legacy industry solutions, we found up to a 16% overestimation of phase transition success rates and an average of 8% overestimation of overall approval success. Read more about the challenges with traditional #benchmarking and how we're addressing the shortcomings https://lnkd.in/eCAP3vxg. #pharma #historicaldata
-